X4 Pharmaceuticals, Inc
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
XFOR$3.25-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(56,596) | $(55,274) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 9,002 | 2,027 |
| Depreciation and amortization expense | 1,551 | 1,054 |
| Non-cash lease expense | 1,144 | 2,290 |
| Accretion of debt discount | 717 | 658 |
| Change in fair value of warrant liability | (948) | (12,796) |
| Other | (69) | 44 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (897) | 179 |
| Inventory | (1,028) | (1,263) |
| Prepaid expenses, other current and non-current assets | (2,236) | 862 |
| Accounts payable | (815) | (3,621) |
| Accrued expenses and other long-term liabilities | (9,838) | (4,190) |
| Deferred revenue | 243 | 1,381 |
| Lease liabilities | (803) | (1,442) |
| Net cash used in operating activities | (60,573) | (70,091) |
| Cash flows from investing activities: | ||
| Acquisition of intangible asset | (5,000) | (3,000) |
| Purchase of marketable securities | — | (61,487) |
| Sales and maturities of marketable securities | 34,252 | 55,792 |
| Net cash provided by (used in) investing activities | 29,252 | (8,695) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of shares of common stock under employee stock purchase plan | 76 | 46 |
| Proceeds from sales of shares of common stock, less issuance costs, and exercise of pre-funded warrants | 1 | 92,490 |
| Payments for debt issuance costs | (112) | — |
| Net cash (used in) provided by financing activities | (35) | 92,536 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (20) | 210 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (31,376) | 13,960 |
| Cash, cash equivalents and restricted cash at beginning of period | 217,852 | 56,475 |
| Cash, cash equivalents and restricted cash at end of period | $186,476 | $70,435 |
| Supplemental Cash Flow Information | ||
| Issuance costs not yet paid related to sale of shares of common stock and pre-funded warrants | $— | $222 |
| Debt issuance cost not yet paid | $205 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.